...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European respiratory review >Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
【24h】

Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche

机译：间质性肺疾病的个性化药物：Renaud Louis和Nicolas Roche编辑的“呼吸系统疾病的个性化药物”系列中的第6名

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised medicine a highly attractive concept. Personalised medicine is aimed at describing distinct disease subsets taking into account individual lifestyle, environmental exposures, genetic profiles and molecular pathways. The cornerstone of personalised medicine is the identification of biomarkers that can be used to inform diagnosis, prognosis and treatment stratification. At present, no data exist validating a personalised approach in individual diseases. However, the importance of the goal amply justifies the characterisation of genotype and pathway signatures with a view to refining prognostic evaluation and trial design, with the ultimate aim of selecting treatments according to profiles in individual patients.
机译：一般而言，间质性肺疾病，尤其是特发性肺纤维化，是具有多种致病途径，各种疾病行为特征和对治疗的不同反应的复杂疾病，所有这些方面都使个性化医学成为高度有吸引力的概念。个性化医学旨在考虑个体生活方式，环境暴露，遗传特征和分子途径来描述不同的疾病亚群。个性化医学的基石是生物标志物的鉴定，可用于告知诊断，预后和治疗分层。目前，尚无数据可用于验证个体疾病的个性化治疗方法。但是，该目标的重要性充分说明了基因型和通路特征的特征，以完善预后评估和试验设计，其最终目的是根据个体患者的情况选择治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号